BeiGene (ONC) announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency issued a positive opinion recommending approval of Tevimbra, in combination with gemcitabine and cisplatin, for the first-line treatment of adult patients with recurrent, not amenable to curative surgery or radiotherapy, or metastatic NPC.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ONC:
- BeiGene: Strong Sales and Promising Pipeline Drive Buy Rating
- BeiGene Holds Annual Shareholders Meeting, Key Resolutions Passed
- BeiGene price target raised to $350 from $348 at Guggenheim
- BeiGene’s Strong Market Position and Promising Financial Outlook Drive Buy Rating
- BeiGene Reports Strong Q1 2025 Growth and Profitability
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue